Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Quince Therapeutics (QNCX)
NASDAQ:QNCX
RESEARCH TOOLSreports
QNCX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.51 - $2.45
Previous CloseN/A
Volume30.57K
Average Volume (3M)128.21K
Market Cap
$63.80M
Enterprise Value$1.11M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Mar 04, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding44,001,644
10 Day Avg. Volume127,821
30 Day Avg. Volume128,207
Standard Deviation0.29
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.44
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$9.00Price Target Upside542.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityQuince Therapeutics has sufficient cash to fund operations into early 2026, supporting its financial stability and ongoing research and development efforts.
Innovation And TechnologyQuince Therapeutics is advancing its AIDE technology platform that allows for encapsulation of a drug into a patient’s own red blood cells, offering potential innovative treatment options.
Bears Say
Previous ChallengesThe EryDex P3 study stems from a prior miss in another P3 (ATTeST) while with EryDel, indicating previous challenges in achieving primary endpoints.
---
Ownership Overview
18.09% Insiders
3.63% Mutual Funds
3.83% Other Institutional Investors
71.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $0.51 and its highest was $2.45 in the past 12 months.
What is Quince Therapeutics’s market cap?
Quince Therapeutics’s market cap is $63.80M.
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 9 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.173 by $0.043.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 44,001,644 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.173. Following the earnings report the stock price went up 19.497%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
---
Quince Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (542.86% Upside)
$9.00 (542.86% Upside)
Blogger Sentiment
Bullish
QNCX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.47%
12-Months-Change
Fundamentals
Return on Equity
-83.18%
Trailing 12-Months
Asset Growth
48.17%
Trailing 12-Months
Company Description
Quince Therapeutics
Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
---
QNCX Stock 12 Month Forecast
Average Price Target
$9.00
▲(542.86% Upside)
Technical Analysis
Fate Therapeutics
―
Cara Therapeutics
―
Adaptimmune Therapeutics
―
Seres Therapeutics
―
Immunovant
―
Best Analysts Covering QNCX
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+64.70%
initiated a buy rating 4 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +64.70% per trade.
---